Pfizer (XSWX:PFE) Ending Cash Position: CHF1,386 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:PFE Pfizer Inc XSWX:PFE
63 GF Score
Price CHF19.64
GF Value CHF21.07
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Pfizer Ending Cash Position?

Pfizer XSWX:PFE -0.85% 63 Ending Cash Position is CHF1,386 Mil as of Mar. 2026. GuruFocus rates XSWX:PFE with a GF Score™ of 63/100 and a GF Value™ of CHF21.07 (Fairly Valued). The stock has 5 warning signs investors should review.

Pfizer's Ending Cash Position for the quarter that ended in Mar. 2026 was CHF1,386 Mil.

Pfizer's quarterly Ending Cash Position declined from Sep. 2025 (CHF1,110 Mil) to Dec. 2025 (CHF954 Mil) but then increased from Dec. 2025 (CHF954 Mil) to Mar. 2026 (CHF1,386 Mil).

Pfizer's annual Ending Cash Position declined from Dec. 2023 (CHF2,523 Mil) to Dec. 2024 (CHF987 Mil) and declined from Dec. 2024 (CHF987 Mil) to Dec. 2025 (CHF954 Mil).

Pfizer Ending Cash Position Related Terms

Pfizer Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Pfizer's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pfizer Ending Cash Position Chart

Pfizer Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,826.34 435.99 2,522.62 987.00 953.89

Pfizer Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,308.61 1,377.56 1,109.76 953.89 1,385.65
XSWX:PFE
63GF Score
Pfizer Inc XSWX:PFE
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pfizer Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Pfizer's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=882.168+71.721000000001
=954

Pfizer's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=942.397+443.251
=1,386

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of CHF1,386 Mil mean?
Pfizer (XSWX:PFE) has a Ending Cash Position of CHF1,386 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Pfizer and its competitors.
Is Pfizer's Ending Cash Position too high?
Pfizer's current Ending Cash Position is CHF1,386 Mil. Overall, Pfizer has a GF Score™ of 63/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pfizer's Ending Cash Position compare to GILD and BMY?
Pfizer's Ending Cash Position of CHF1,386 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Pfizer and its competitors. Pfizer's current Ending Cash Position is CHF1,386 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pfizer stock overvalued right now?
Based on GuruFocus' analysis, Pfizer (XSWX:PFE) is currently considered Fairly Valued. The stock's GF Value™ is CHF21.07, compared to a current price of CHF19.64 — trading 6.8% below its estimated fair value. The current Ending Cash Position is CHF1,386 Mil. Pfizer's overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Pfizer (XSWX:PFE), the current Ending Cash Position is CHF1,386 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pfizer (XSWX:PFE) Overvalued in 2026?

Based on GuruFocus' analysis, Pfizer stock appears to be undervalued. The current stock price of CHF19.64 is trading 6.8% below its estimated GF Value™ of CHF21.07. GuruFocus considers Pfizer to be Fairly Valued.

Key valuation signals for XSWX:PFE:

  • Ending Cash Position: CHF1,386 Mil
  • GF Value™: CHF21.07 vs. price of CHF19.64 (6.8% below fair value)
  • GF Score™: 63/100 with 5 warning signs

No single metric tells the full story. See the XSWX:PFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pfizer Business Description

Address 66 Hudson Boulevard East, New York, NY, USA, 10001-2192
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
63GF Score

Get the complete analysis for XSWX:PFE

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF19.64
Price
CHF21.07
GF Value